Influence of human plasma versus serum on transfection efficiency of mRNA nanoparticles

Influence of human plasma versus serum on transfection efficiency of mRNA nanoparticles - SerPmRNA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51048

Enrollment

Registered

2021-07-07

Start date

2021-06-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geen: het betreft fundamenteel onderzoek naar de werking van PepFect14-mRNA nanodeeltjes -

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Healthy indivuals, 18-60 years of age, bodyweight: above 50 kg. Being able and willing to complete the informed consent process.

Exclusion criteria

Exclusion criteria: Known to have a condition which results in more than minimal risk upon blood drawing, e.g. hemophilia. A medical condition which requires active medical intervention or monitoring to avert serious danger to the individual's health or well-being.

Design outcomes

Primary

Measure	Time frame
The main parameters are the Cy5-mRNA uptake and EGFP expression after transfection of cells with PF14-EGFP mRNA or PF14 with Cy5-labeled EGFP mRNA, in the presence of plasma or serum. Cy5 and EGFP levels will be measured by confocal laser scanning microscopy (CLSM).	—

Secondary

Measure	Time frame
N.a.	—

Countries

Netherlands

Outcome results